

Sawai Group corporate philosophy

Dedicated to building a healthier future for all

The Sawai Group corporate philosophy of “dedicated to building a healthier future for all” embodies our desire to contribute to the health of as many people as possible as a healthcare corporate group which develops sustainably alongside society, with the generic drugs business as our core business. We will mobilize the strengths of all Group employees to pursue the challenge of meeting the expectations of all stakeholders.

Sawai Group Mind



The Sawai Group will serve every stakeholder wholeheartedly.
The Sawai Group will continue the challenge to improve access to healthcare for more people.
The Sawai Group aspires to play a pivotal role in healthcare through its contribution to society.

Contents

5	Management message	19	Value creation strategy	43	Governance
5	Message from the CEO	19	Generic drugs market landscape	43	Dialogue with investors and directors
11	Medium-term Business Plan “Beyond 2027”	21	Japan generic drug business	47	Board of Directors
		25	New businesses	49	Corporate governance
13	Our value creation story	27	Message from the CFO	53	Eleven-year financial and non-financial summary
13	Our value creation model	29	Research & development		
15	Sustainability at the Sawai Group	31	Intellectual property		
		33	Growing production capacity		
		35	Human capital strategy		
		39	Society		
		41	Environment		

Fulfilling the Sawai Group Corporate Philosophy



Editorial policy

This report references the International Financial Reporting Standards Foundation's International Integrated Report Framework and includes information that could impact our medium to long-term corporate value creation and that is connected with information about the Company's strategies, performance, and future projections, as well as non-financial information concerning the environment, society, and governance. The contents herein have been assigned priority internally based on their nature and quantity, risks, opportunities, and dialogues with stakeholders, and have been deemed to be of particular importance.

This report has been prepared by the Group Sustainability Committee, which is supervised by the President, and with the support of the committee's administrative office.

Reporting period:
April 1, 2024 to March 31, 2025
(some information herein falls outside of this period)

Abbreviations used:
In this report, “generic drugs” are abbreviated as either “GE drugs” or “GE.”

A caution concerning forward-looking statements:
This report contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at the time of publication. Accordingly, please be aware that the impact of certain risks and uncertainties could cause the Company's actual results to differ materially from any projections presented in this report.

Reporting scope:
Sawai Group Holdings and its consolidated subsidiaries

Group history

Not only “always putting patients first”
but also striving to succeed in
“dedicated to building
a healthier future”
for all people



New solid dosage facility
at Daini Kyushu Factory
Completed in July 2024

